Skip to search formSkip to main contentSkip to account menu

The New Generation of GABA Enhancers

Ganaxolone, retigabine and pregabalin may prove to have a more advantageous therapeutic profile than the presently licensed GABA enhancing drugs, and CGP 36742, a GABAb receptor antagonist, may be particularly useful in the management of primary generalised absence seizures.
View on Springer (opens in a new tab)

Basic mechanisms of antiepileptic drugs and their pharmacokinetic/pharmacodynamic interactions: an update.

View on PubMed (opens in a new tab)

Preclinical Profile of Combinations of Some Second‐generation Antiepileptic Drugs: An Isobolographic Analysis

This study sought to determine the interactions among some newer AEDs in the maximal electroshock‐induced seizures (MES) and chimney test (motor performance) in mice, by using the isobolographic analysis.
View on Wiley (opens in a new tab)

Interactions of Lamotrigine with Topiramate and First‐generation Antiepileptic Drugs in the Maximal Electroshock Test in Mice: An Isobolographic Analysis

This study investigated the types of interactions between lamotrigine (LTG) and first‐generation antiepileptic drugs (AEDs) or topiramate (TPM) with isobolographic analysis.
View on Wiley (opens in a new tab)

Time–course and dose–response relationships of imperatorin in the mouse maximal electroshock seizure threshold model

View on Elsevier (opens in a new tab)

Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice.

View on PubMed (opens in a new tab)

Anticonvulsant profile of caprylic acid, a main constituent of the medium-chain triglyceride (MCT) ketogenic diet, in mice

View on Elsevier (opens in a new tab)

Arachidonyl-2'-chloroethylamide, a highly selective cannabinoid CB1 receptor agonist, enhances the anticonvulsant action of valproate in the mouse maximal electroshock-induced seizure model.

View on PubMed (opens in a new tab)

Zonisamide: a new antiepileptic drug.

Zonisamide (ZNS) is a new antiepileptic drug (AED) efficient in treating refractory epilepsy and its efficacy in different types of seizures was confirmed in various animal studies as well as in clinical conditions.
View on PubMed (opens in a new tab)

Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy

View on Elsevier (opens in a new tab)
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)